IMUX
Price
$9.31
Change
+$0.40 (+4.49%)
Updated
Sep 30, 04:59 PM (EDT)
Capitalization
129.76M
29 days until earnings call
Intraday BUY SELL Signals
REVB
Price
$0.82
Change
+$0.01 (+1.23%)
Updated
Sep 30, 04:59 PM (EDT)
Capitalization
3.42M
36 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IMUX vs REVB

IMUX vs REVB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IMUX vs. REVB commentary
Sep 30, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMUX is a Buy and REVB is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
IMUX vs REVB: Fundamental Ratings
IMUX
REVB
OUTLOOK RATING
1..100
961
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
7
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
6587
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REVB's Valuation (7) in the null industry is in the same range as IMUX (13) in the Pharmaceuticals Major industry. This means that REVB’s stock grew similarly to IMUX’s over the last 12 months.

REVB's Profit vs Risk Rating (100) in the null industry is in the same range as IMUX (100) in the Pharmaceuticals Major industry. This means that REVB’s stock grew similarly to IMUX’s over the last 12 months.

IMUX's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as REVB (100) in the null industry. This means that IMUX’s stock grew similarly to REVB’s over the last 12 months.

IMUX's Price Growth Rating (65) in the Pharmaceuticals Major industry is in the same range as REVB (87) in the null industry. This means that IMUX’s stock grew similarly to REVB’s over the last 12 months.

REVB's P/E Growth Rating (2) in the null industry is significantly better than the same rating for IMUX (100) in the Pharmaceuticals Major industry. This means that REVB’s stock grew significantly faster than IMUX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMUXREVB
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 14 days ago
80%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Sep 30, 2026
Stock price -- (IMUX: $8.91 vs. REVB: $0.81)
Brand notoriety: IMUX and REVB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMUX: 162% vs. REVB: 146%
Market capitalization -- IMUX: $129.76M vs. REVB: $3.42M
IMUX [@Biotechnology] is valued at $129.76M. REVB’s [@Biotechnology] market capitalization is $3.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMUX’s FA Score shows that 1 FA rating(s) are green while REVB’s FA Score has 2 green FA rating(s).

  • IMUX’s FA Score: 1 green, 4 red.
  • REVB’s FA Score: 2 green, 3 red.
According to our system of comparison, REVB is a better buy in the long-term than IMUX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMUX’s TA Score shows that 4 TA indicator(s) are bullish while REVB’s TA Score has 4 bullish TA indicator(s).

  • IMUX’s TA Score: 4 bullish, 6 bearish.
  • REVB’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, REVB is a better buy in the short-term than IMUX.

Price Growth

IMUX (@Biotechnology) experienced а -17.80% price change this week, while REVB (@Biotechnology) price change was -16.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.96%. For the same industry, the average monthly price growth was -10.73%, and the average quarterly price growth was +1.14%.

Reported Earning Dates

IMUX is expected to report earnings on Oct 29, 2026.

REVB is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-0.96% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
IMUX
Daily Signal:
Gain/Loss:
REVB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SXTC2.810.29
+11.51%
China Sxt Pharmaceuticals Inc
ENVX2.750.19
+7.63%
Enovix Corp
LGL6.850.14
+2.08%
LGL Group (The)
MZTI99.90-1.20
-1.19%
The Marzetti Company
AS27.24-0.38
-1.38%
Amer Sports

IMUX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMUX has been loosely correlated with ERAS. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if IMUX jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMUX
1D Price
Change %
IMUX100%
-6.31%
ERAS - IMUX
35%
Loosely correlated
+0.57%
VYGR - IMUX
34%
Loosely correlated
-2.22%
ORIC - IMUX
34%
Loosely correlated
+0.75%
KURA - IMUX
34%
Loosely correlated
+1.84%
REVB - IMUX
33%
Loosely correlated
-4.85%
More

REVB and

Correlation & Price change

A.I.dvisor indicates that over the last year, REVB has been closely correlated with INKT. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if REVB jumps, then INKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REVB
1D Price
Change %
REVB100%
-4.85%
INKT - REVB
80%
Closely correlated
+1.07%
GNPX - REVB
48%
Loosely correlated
+1.42%
SABS - REVB
48%
Loosely correlated
+0.16%
TCRT - REVB
46%
Loosely correlated
-5.83%
ANL - REVB
33%
Loosely correlated
+1.62%
More